View Clinical Trial (Medical Research Study)

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease - NCT00566397-15213(Clinical Trial 192584)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Pittsburgh
State:  
PA
Zip Code: 15213
Conditions: Alzheimer's Disease
Purpose: The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.
Study summary:
Criteria: Inclusion Criteria: - Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening. - Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization Exclusion Criteria: - Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia. - Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations. - Evidence or history of diabetes mellitus Type 1 or Type 2. - History or symptoms of autoimmune disorders.
Study is available at: Pfizer Investigational Site
Pittsburgh, PA 15213
United States

Primary Contact:
Pfizer CT.gov Call Center
Phone: 1-800-718-1021
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.